AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04996550
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Trial: NCT04996550
Drug: Metoprolol Succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Trial: NCT06412952
Drug: 68Ga-RM26
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-RM26. Tracer doses of 68Ga- RM26 will be used to image lesions of glioma by PET/CT.
Trial: NCT03063190
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive vitamin D supplementation according to guidelines
Trial: NCT06121271
Drug: Lu-177 DOTATATE (Lutathera®)
RxNorm normalized name: lutetium Lu 177 dotatate Injection [Lutathera]
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.
Trial: NCT04272333
Drug: Motolimod
RxNorm normalized name: Motolimod
DrugBank: Motolimod (DB12303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral microdose injection by the CIVO device.
Trial: NCT05255848
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given the same standard of care treatment plus nebulized heparin 5000IU every 8 hours started 24 hours after randomization, using a compressed air nebulizer, and will be continued for one week. In case of any complication, if the attending physician feels it necessary intervention treatment will be stopped
Trial: NCT06449339
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the NSBB arm will receive generic carvedilol. The starting dose of oral carvedilol is 6.25mg daily (to be taken once or twice per day) and can be adjusted at each scheduled visit (either by increasing the dosage or frequency of dose administration) according to patients' tolerance, as well as the blood pressure and pulse rate that the systolic blood pressure should be not lower than 90 mmHg and pulse rate not lower than 55 beats per minute. The dosage of carvedilol can also be titrated or discontinued at unscheduled visit according to patient's condition. In case carvedilol is discontinued, it can be resumed from the starting dose at next scheduled visit if there is no contraindication for carvedilol. The dose of carvedilol will be kept at 6.25-12.5mg per day unless there are additional non-hepatic indications such as arterial hypertension or cardiac disease warranting higher carvedilol dosage. The maximum allowed dose of carvedilol is 50mg daily as per drug instruction.
Trial: NCT05042609
Drug: TRS01
RxNorm normalized name: Trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TRS01 eye drops Dosed four times a day (QID)
Trial: NCT06184958
Drug: Lidocaine group
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A: Lidocaine group( 25 patients) will receive 5 mg/Kg lidocaine in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
Trial: NCT06184958
Drug: Ketamine group
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group B:Ketamine group(25 patients) will receive 0.5 mg/Kg ketamine sulphate in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
Trial: NCT05716035
Drug: Tocilizumab Injection
RxNorm normalized name: tocilizumab Injection
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive IV tocilizumab
Trial: NCT05549154
Drug: High-dose vitamin D2 softgels
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000U/capsule of vitamin D2 soft capsule; High-dose VD group 50,000 U/week, 5 vitamin D2 softgels given twice a week each time; 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given)
Trial: NCT05549154
Drug: low-dose vitamin D2 softgels
RxNorm normalized name: ethinyl estradiol
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000U/capsule of vitamin D2 soft capsule; low-dose VD group 25,000 U/week, 3 vitamin D2 softgels + 2 placebo in the first dose, 2 vitamin D2 softgels + 3 placebo in the second dose, 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given);
Trial: NCT04574947
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.
Trial: NCT06229054
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX), an α2-agonist with more promising pharmacokinetic and pharmacodynamic characteristics than clonidine has been proved to have a positive effect on postoperative pain intensity and to reduce opioid consumption
Trial: NCT06229054
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local anesthesic which works through blocking sodium channels
Trial: NCT05608785
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
Trial: NCT05608785
Drug: TST001
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN CLAUDIN 18.2) (HUMAN-MUS MUSCULUS MONOCLONAL TST001 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TST001 .KAPPA.-CHAIN, DIMER
DrugBank: Osemitamab (DB18219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TST001 is a high-affinity humanized monoclonal antibody targeting Claudin 18.2 with enhanced antibody-dependent cytotoxic (ADCC) and complement-dependent cytotoxic (CDC) activity, showing potent antitumor activity in xenograft assays.
Trial: NCT06065436
Drug: Collagenase Clostridium Histolyticum
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.
Trial: NCT05265507
Drug: Glycopyrronium
RxNorm normalized name: glycopyrronium
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.
Trial: NCT05265507
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycopyrronium (4mg) was intravenously given at the ending of the surgery.
Trial: NCT05493267
Drug: Vγ2Vδ2 T lymphocyte-based immunotherapy
RxNorm normalized name: Lapine T-lymphocyte immune globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
Trial: NCT05216367
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib will be administered as a single oral dose on the morning of day 1 under fasting conditions
Trial: NCT06288230
Drug: vesemnogene lantuparvovec
RxNorm normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exploratory study evaluating the safety and efficacy of vesemnogene lantuparvovec in patients with SMA.
Trial: NCT05585216
Drug: platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
Trial: NCT00000707
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05624099
Drug: camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg intravenous drip d1q3w
Trial: NCT05624099
Drug: Paclitaxel drugs
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150mg/m2 d1 q3w
Trial: NCT05624099
Drug: Platinum drug
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin, carboplatin, nedaplatin and other platinum drugs
Trial: NCT04857827
Drug: Timolol maleate PF 0.5% ophthalmic solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
Trial: NCT05233410
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Trial: NCT01461304
Drug: triheptanoin
RxNorm normalized name: Triheptanoin
DrugBank: Triheptanoin (DB11677)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subjects will receive a modified diet containing triheptanoin (up to 2 grams/kg/24 hours; subjects who experience cardiomyopathy may receive doses up to 4 grams/kg/24 hours), or continued on their previously established triheptanoin dose; not to exceed RDA for fat, substituted for their MCT oil and/or natural fat. Study subjects will continue the triheptanoin-supplemented diet for a period of 12 months and then be able to continue into an indefinite extension phase in this compassionate use study. Laboratory evaluations will take place at two, six, and twelve months as well as every 12 months in the extension phase.
Trial: NCT06256991
Drug: Patiromer 8400 MG [Veltassa]
RxNorm normalized name: patiromer 8400 MG [Veltassa]
DrugBank: Patiromer (DB09263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.
Trial: NCT06207734
Drug: Continuation of CDK4/6 inhibitor Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuation of CDK4/6 inhibitor Palbociclib
Trial: NCT06207734
Drug: Discontinuation of CDK4/6 inhibitor Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Discontinuation of CDK4/6 inhibitor Palbociclib
Trial: NCT06207734
Drug: Continuation of CDK4/6 inhibitor -Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuation of CDK4/6 inhibitor -Palbociclib
Trial: NCT06207734
Drug: Discontinuation of CDK4/6 inhibitor -Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Discontinuation of CDK4/6 inhibitor -Palbociclib
Trial: NCT06207734
Drug: Continuation of CDK4/6 inhibitor Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuation of CDK4/6 inhibitor Abemaciclib
Trial: NCT06207734
Drug: Discontinuation of CDK4/6 inhibitor Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Discontinuation of CDK4/6 inhibitor Abemaciclib
Trial: NCT05320393
Drug: OnabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: One treatment of 20 units
Trial: NCT04835168
Drug: BT-11 low
RxNorm normalized name: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 100000 MW)
DrugBank: Hydroxypropyl cellulose (DB00840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04835168
Drug: BT-11 high
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04126824
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone administered as a Superior Hypogastric Nerve Block (SHNB)
Trial: NCT04126824
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine (20 mL) administered as a Superior Hypogastric Nerve Block (SHNB).
Trial: NCT06437912
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
Trial: NCT04759365
Drug: ASN51
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASN51 formulation for oral capsule
Trial: NCT00000735
Drug: Ampligen
DrugBank: Rintatolimod (DB16425)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05491421
Drug: ZT002
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings
Trial: NCT04409795
Drug: Metformin Extended Release Oral Tablet
RxNorm normalized name: metformin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Initial oral hypoglycemic agent added to existing insulin treatment
Trial: NCT04409795
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)
Trial: NCT06112340
Drug: linsitinib
RxNorm normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication taken twice daily by mouth
Trial: NCT05382286
Drug: Sacituzumab Govitecan-hziy
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously
Trial: NCT05382286
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05382286
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05382286
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05382286
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05382286
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT00001996
Drug: Atovaquone
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001996
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04709770
Drug: 2-liters polyethylene glycol with citrate and simethicone
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
Trial: NCT04709770
Drug: 4-liters polyethylene glycol with simethicone
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
Trial: NCT05900427
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
Trial: NCT05900427
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
Trial: NCT04991480
Drug: Talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.
Trial: NCT04991480
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.
Trial: NCT05508061
Drug: Insulin Lispro Cartridge [Lyumjev]
RxNorm normalized name: insulin lispro Cartridge [Lyumjev]
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of Lyumjev in combination with the AP system
Trial: NCT05508061
Drug: Insulin Lispro Cartridge
RxNorm normalized name: insulin lispro Cartridge
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of Humalog in combination with the AP system (standard therapy)
Trial: NCT06087978
Drug: 14C RPT193
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Radiolabelled RPT193
Trial: NCT06192979
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice.
Trial: NCT06192979
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.
Trial: NCT06192979
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients received 20-40 mg oral or intravenous dexamethasone
Trial: NCT06192979
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients received venetoclax 400mg daily.
Trial: NCT05430620
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion
Trial: NCT05848765
Drug: Epcoritamab
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific antibody